Noninvasive cardiac imaging

Coronary artery disease (CAD), also referred to as coronary heart disease (CHD) or ischemic heart disease (IHD), is a leading cause of death for both men and women in the United States and is the most common form of cardiovascular disease.  Accurate and early assessment of patients with symptomatic CAD is important for risk management and initiation of appropriate treatments to reduce morbidity and mortality. Noninvasive anatomic tests provide information on location and extent of blockage and include coronary CT angiography (CCTA) and cardiac magnetic resonance imaging (CMRI).

Status: Decision completed

Why is noninvasive cardiac imaging being reviewed?

The Health Technology Assessment (HTA) program conducted assessments on Coronary Computed Tomographic Angiography (CCTA) and cardiac nuclear imaging in 2008 and 2013 respectively. The current assessment will reevaluate imaging for diagnosis of CAD based on newer evidence on CCTA and stress cardiac nuclear imaging.

Primary criteria ranking

  • Safety = Medium
  • Efficacy = Medium
  • Cost = High

Documentation

Assessment timeline

  • Draft key questions published: January 26, 2021
    • Public comment period: January 27 to February 11, 2021
  • Final key questions published: April 22, 2021
  • Draft report published: September 10, 2021
    • Public comment period: September 10 to October 9, 2021
  • Final report published: October 20, 2021
  • HTCC public meeting: November 5, 2021